HC Wainwright Weighs in on Lineage Cell Therapeutics Q1 Earnings

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) – Equities researchers at HC Wainwright issued their Q1 2025 earnings per share estimates for Lineage Cell Therapeutics in a note issued to investors on Tuesday, March 11th. HC Wainwright analyst J. Pantginis anticipates that the company will earn ($0.01) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Lineage Cell Therapeutics’ current full-year earnings is ($0.12) per share. HC Wainwright also issued estimates for Lineage Cell Therapeutics’ Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at ($0.02) EPS and FY2025 earnings at ($0.06) EPS.

Other research analysts have also recently issued research reports about the company. Maxim Group reduced their target price on Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, January 10th. D. Boral Capital reaffirmed a “buy” rating and issued a $2.00 price objective on shares of Lineage Cell Therapeutics in a research note on Tuesday.

Lineage Cell Therapeutics Stock Performance

Shares of LCTX opened at $0.52 on Thursday. The firm has a market cap of $114.62 million, a price-to-earnings ratio of -4.33 and a beta of 1.21. The company has a fifty day moving average of $0.60. Lineage Cell Therapeutics has a fifty-two week low of $0.48 and a fifty-two week high of $1.61.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Fort Sheridan Advisors LLC boosted its stake in Lineage Cell Therapeutics by 71.5% in the fourth quarter. Fort Sheridan Advisors LLC now owns 55,177 shares of the company’s stock valued at $28,000 after acquiring an additional 23,000 shares during the period. Atria Wealth Solutions Inc. bought a new stake in shares of Lineage Cell Therapeutics in the 4th quarter worth approximately $29,000. HighTower Advisors LLC boosted its position in Lineage Cell Therapeutics by 49.5% during the 4th quarter. HighTower Advisors LLC now owns 57,706 shares of the company’s stock valued at $29,000 after purchasing an additional 19,100 shares during the period. SG Americas Securities LLC grew its stake in Lineage Cell Therapeutics by 35.5% during the 4th quarter. SG Americas Securities LLC now owns 68,973 shares of the company’s stock worth $35,000 after buying an additional 18,053 shares during the last quarter. Finally, Two Sigma Advisers LP increased its position in Lineage Cell Therapeutics by 312.2% in the fourth quarter. Two Sigma Advisers LP now owns 86,964 shares of the company’s stock worth $44,000 after buying an additional 65,864 shares during the period. 62.47% of the stock is owned by institutional investors and hedge funds.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.